Changes in T- and B-cell immune abnormalities and inflammatory milieu in patients with m-IC on sirolimus therapy. (A) FACS plots showing frequency of co-expression of activation markers HLA-DR⁺ CD38⁺ on CD4⁺ EM T cells in a patient with m-IC before (Pre) and after (Post) sirolimus therapy. (B-C) Dot plots showing percentage of CD4⁺ EM activation (HLA-DR⁺CD38⁺ gated on CD4⁺ EM T cells) and naïve CD4⁺ T in HC and m-IC groups. (D-E) Plots showing percentage of immune markers for exhaustion (PD-1⁺ Tim3⁺) and senescence (CD57⁺) gated on CD4⁺ EM T cells in HC and m-IC groups. (F) Dots plots represent CSMB cells in HC and m-IC groups. (G) Dot plot represents a combined immune score of 4 immune parameters in pre- and post-sirolimus treatment m-IC groups (n = 9). (H) Bar plots showing plasma concentrations of sCD40L, IL-21, IFN-γ, CXCL9, CXCL10, IL-12p40, IL-10, IL-18, IL-2 and IL-7 in pre- and posttreatment m-IC groups. Kruskal-Wallis 1-way ANOVA followed by Dunn’s multiple comparison test for non-normally distributed samples and ordinary 1-way ANOVA followed by Tukey’s multiple comparison test for normally distributed samples were used for statistical comparison of HC with m-IC pre- and posttreatment groups. Paired t test or Wilcoxon signed-rank test was used for paired analysis between pre- and post-m-IC groups. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001; ns, not significant.